{
  "ticker": "ARQT",
  "company_name": "Arcutis Biotherapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04091646",
      "title": "Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Seborrheic Dermatitis",
      "start_date": "2019-12-04",
      "completion_date": "2020-08-21",
      "enrollment": 0,
      "sponsor": "Arcutis Biotherapeutics, Inc."
    },
    {
      "nct_id": "NCT04211389",
      "title": "Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Chronic Plaque Psoriasis",
      "start_date": "2019-12-17",
      "completion_date": "2020-11-23",
      "enrollment": 0,
      "sponsor": "Arcutis Biotherapeutics, Inc."
    },
    {
      "nct_id": "NCT04128007",
      "title": "Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Plaque Psoriasis",
      "start_date": "2020-01-13",
      "completion_date": "2020-09-25",
      "enrollment": 0,
      "sponsor": "Arcutis Biotherapeutics, Inc."
    },
    {
      "nct_id": "NCT04811131",
      "title": "Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Vitiligo",
      "start_date": "2021-03-04",
      "completion_date": "2021-08-09",
      "enrollment": 0,
      "sponsor": "Arcutis Biotherapeutics, Inc."
    },
    {
      "nct_id": "NCT04156191",
      "title": "Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Atopic Dermatitis (Eczema)",
      "start_date": "2019-12-23",
      "completion_date": "2023-05-02",
      "enrollment": 0,
      "sponsor": "Arcutis Biotherapeutics, Inc."
    },
    {
      "nct_id": "NCT04773587",
      "title": "Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Atopic Dermatitis Eczema",
      "start_date": "2021-01-27",
      "completion_date": "2022-08-30",
      "enrollment": 0,
      "sponsor": "Arcutis Biotherapeutics, Inc."
    },
    {
      "nct_id": "NCT06998056",
      "title": "Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Atopic Dermatitis (Eczema)",
      "start_date": "2025-06-09",
      "completion_date": "2025-12-04",
      "enrollment": 0,
      "sponsor": "Arcutis Biotherapeutics, Inc."
    },
    {
      "nct_id": "NCT03392168",
      "title": "Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Psoriasis",
      "start_date": "2017-12-11",
      "completion_date": "2018-05-02",
      "enrollment": 0,
      "sponsor": "Arcutis Biotherapeutics, Inc."
    },
    {
      "nct_id": "NCT04973228",
      "title": "Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Seborrheic Dermatitis",
      "start_date": "2021-07-08",
      "completion_date": "2022-04-06",
      "enrollment": 0,
      "sponsor": "Arcutis Biotherapeutics, Inc."
    },
    {
      "nct_id": "NCT04211363",
      "title": "Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Chronic Plaque Psoriasis",
      "start_date": "2019-12-20",
      "completion_date": "2020-11-16",
      "enrollment": 0,
      "sponsor": "Arcutis Biotherapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 26,
    "by_phase": {
      "PHASE2": 12,
      "PHASE3": 9,
      "PHASE1": 3,
      "PHASE1, PHASE2": 2
    },
    "by_status": {
      "COMPLETED": 22,
      "TERMINATED": 1,
      "RECRUITING": 3
    },
    "active_trials": 3,
    "completed_trials": 22,
    "conditions": [
      "Atopic Dermatitis",
      "Atopic Dermatitis (Eczema)",
      "Atopic Dermatitis Eczema",
      "Chronic Hand Eczema",
      "Chronic Plaque Psoriasis",
      "Hidradenitis Suppurativa",
      "Non-segmental Vitiligo",
      "Plaque Psoriasis",
      "Psoriasis",
      "Psoriasis, Plaque Psoriasis",
      "Scalp Psoriasis",
      "Seborrheic Dermatitis",
      "Vitiligo"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:35.578636",
    "search_query": "Arcutis Biotherapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Arcutis+Biotherapeutics,+Inc."
  }
}